v3.25.2
SCHEDULE OF UNAUDITED PRO FORMA FINANCIAL INFORMATION (Details) - USD ($)
 2 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2024
May 31, 2025
Mar. 31, 2025
Mar. 31, 2024
Sep. 30, 2024
Sep. 30, 2023
Oct. 03, 2024
Sep. 30, 2022
Jul. 25, 2018
Restructuring Cost and Reserve [Line Items]                  
Cash                
TOTAL ASSETS                
Total Current Liabilities 5,984 $ 34,528              
TOTAL LIABILITIES 5,984 34,528              
Ordinary shares (US$1 par value; 50,000 shares; authorized 13,727 shares issued) $ 0 $ 0              
Ordinary shares, par value $ 0.0001 $ 0.0001              
Ordinary shares, shares authorized 500,000,000 500,000,000              
Ordinary shares, shares issued 1 1              
Additional paid-in capital $ (0) $ (0)              
Accumulated other comprehensive loss   1              
Accumulated deficit (5,984) (34,529)              
Total Shareholders’ Deficit (5,984) (34,528)            
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT              
Net Loss $ (5,984) $ (28,545)              
Net loss per share attributable to ordinary shareholders - basic $ (5,984) $ (28,544)              
Net loss per share attributable to ordinary shareholders - diluted $ (5,984) $ (28,544)              
Weighted average number of ordinary shares used in computing net loss per share - basic 1 1              
Weighted average number of ordinary shares used in computing net loss per share - diluted 1 1              
Maius Pharmaceutical Co. Ltd [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Cash     $ 1,809,035   $ 74,514 $ 179,237      
Current assets         371,593        
Total Current Assets     2,249,927   446,107 575,441      
Total non-current assets     611,632   413,666 256,697      
TOTAL ASSETS     2,861,559   859,773 832,138      
Total Current Liabilities     4,010,149   3,356,493 2,701,505      
Non-current liabilities         26,277        
TOTAL LIABILITIES     4,013,826   3,382,770 2,701,505      
Ordinary shares (US$1 par value; 50,000 shares; authorized 13,727 shares issued)     $ 14,619   $ 13,727 $ 13,727      
Ordinary shares, par value     $ 1   $ 1.00 $ 1     $ 1.00
Ordinary shares, shares authorized     50,000   50,000 50,000     50,000
Ordinary shares, shares issued     14,619   13,727 13,727      
Additional paid-in capital     $ 13,160,402   $ 11,074,192 $ 11,074,192      
Subscription receivables     (2,939,179)   (2,939,179) (2,969,955)      
Accumulated other comprehensive loss     (156,545)   (220,253) (165,023)      
Accumulated deficit     (11,231,564)   (10,451,484) (9,822,308)      
Total Shareholders’ Deficit     (1,152,267) $ (2,229,227) (2,522,997) (1,869,367)   $ 435,525  
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT     2,861,559   $ 859,773 832,138      
Number of shares issued         892        
Number of shares issued, value         $ 2,087,102        
Net Loss     $ (780,080) $ (367,192) $ (629,176) [1] $ (4,344,768)      
Net loss per share attributable to ordinary shareholders - basic       $ (26.75) $ (45.83) $ (337.62)      
Net loss per share attributable to ordinary shareholders - diluted     $ (54.47) $ (26.75) $ (45.83) $ (337.62)      
Weighted average number of ordinary shares used in computing net loss per share - basic     14,322 13,727 13,727 [2] 12,869      
Weighted average number of ordinary shares used in computing net loss per share - diluted     14,322 13,727 13,727 [2] 12,869      
Maius Pharmaceutical Co. Ltd [Member] | Pro Forma Adjustment [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Cash [3]         $ 2,087,102        
Current assets                
Total Current Assets         2,087,102        
Total non-current assets                
TOTAL ASSETS         2,087,102        
Total Current Liabilities                
Non-current liabilities                
TOTAL LIABILITIES                
Ordinary shares (US$1 par value; 50,000 shares; authorized 13,727 shares issued) [3]         892        
Additional paid-in capital [3]         2,086,210        
Total Shareholders’ Deficit         2,087,102        
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT         2,087,102        
Net Loss [1]                
Net loss per share attributable to ordinary shareholders - basic                
Net loss per share attributable to ordinary shareholders - diluted                
Weighted average number of ordinary shares used in computing net loss per share - basic [2]         892        
Weighted average number of ordinary shares used in computing net loss per share - diluted [2]         892        
Maius Pharmaceutical Co. Ltd [Member] | Pro Forma [Member]                  
Restructuring Cost and Reserve [Line Items]                  
Cash         $ 2,161,616        
Current assets         371,593        
Total Current Assets         2,533,209        
Total non-current assets         413,666        
TOTAL ASSETS         2,946,875        
Total Current Liabilities         3,356,493        
Non-current liabilities         26,277        
TOTAL LIABILITIES         3,382,770        
Ordinary shares (US$1 par value; 50,000 shares; authorized 13,727 shares issued)         14,619        
Additional paid-in capital         13,160,402        
Subscription receivables         (2,939,179)        
Accumulated other comprehensive loss         (220,253)        
Accumulated deficit         (10,451,484)        
Total Shareholders’ Deficit         (435,895)        
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT         2,946,875        
Net Loss [1]         $ (629,176)        
Net loss per share attributable to ordinary shareholders - basic         $ (43.04)        
Net loss per share attributable to ordinary shareholders - diluted         $ (43.04)        
Weighted average number of ordinary shares used in computing net loss per share - basic [2]         14,619        
Weighted average number of ordinary shares used in computing net loss per share - diluted [2]         14,619        
[1] There are no effects on total revenue and total net income.
[2] Additional 892 were shares issued for $2,087,102.
[3] Additional 892 were shares issued for $2,087,102.